Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cancer Immunotherapy & Biofluid Biopsies 2016

Brian Dougherty's Biography



Brian Dougherty, Executive Director, Translational Genomics, Oncology IMED, AstraZeneca R&D

Brian is the Executive Director of Translational Genomics Oncology at AstraZeneca Pharmaceuticals in Boston, MA leading AstraZeneca’s cancer genomics efforts. He oversees a team of lab scientists and computational biologists applying leading-edge genomic and advanced algorithmic technologies to deliver on Precision Medicine - matching the right patient with the right drug. This includes biomarker development, patient selection and monitoring strategies, identifying new tumor drug resistance mechanisms, researching genetics-based translational hypotheses, and delivering novel cancer targets. When he was previously at Bristol-Myers Squibb, Pfizer, TIGR and Amgen, Brian led sequencing, genotyping, gene expression, high-content imaging, and functional genomics lab efforts, applying technologies to enable the discovery and development of medicines for diseases such as cancer, infectious diseases, chronic pain, and Alzheimer’s Disease.

Brian holds a B.A. from the University of Delaware, a Ph.D. from Wake Forest University Medical Center, an M.B.A from the University of New Haven, and completed a postdoctoral research fellowship in the laboratory of Nobel laureate Hamilton O. Smith at The Johns Hopkins University School of Medicine.

Brian Dougherty Image

Development of Next Generation Sequencing Biomarker Assays and Analysis Pipelines for Cancer Immunotherapy

Tuesday, 1 November 2016 at 16:30

Add to Calendar ▼2016-11-01 16:30:002016-11-01 17:30:00Europe/LondonDevelopment of Next Generation Sequencing Biomarker Assays and Analysis Pipelines for Cancer ImmunotherapyCancer Immunotherapy and Biofluid Biopsies 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Immunotherapies for cancer treatment are being developed using antibody, small molecule, and anti-sense modalities. Next Generation Sequencing analysis pipelines have been modified for immunotherapy biomarker assays to include methods for HLA typing, somatic neoantigen presentation, mutational burden, T-cell receptor re-arrangement, and differential gene expression analysis.


Add to Calendar ▼2016-11-01 00:00:002016-11-02 00:00:00Europe/LondonCancer Immunotherapy and Biofluid Biopsies 2016Cancer Immunotherapy and Biofluid Biopsies 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com